TITLE

Recent advances in immunotherapy for non-small-cell lung cancer

AUTHOR(S)
Hiroyuki Suzuki; Yuki Owada; Yuzuru Watanabe; Takuya Inoue; Mitsuro Fukuharav; Takumi Yamaura; Satoshi Mutoh; Naoyuki Okabe; Hiroshi Yaginuma; Takeo Hasegawa; Atsushi Yonechi; Jun Ohsugi; Mika Hoshino; Mitsunori Higuchi; Yutaka Shio; Mitsukazu Gotoh
PUB. DATE
February 2014
SOURCE
Human Vaccines & Immunotherapeutics;Feb2014, Vol. 10 Issue 2, p1
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
No abstract available.
ACCESSION #
94752472

 

Related Articles

  • Recent Advances in Immunotherapy of Lung Cancer. Iclozan, Cristina; Gabrilovich, Dmitry I. // Journal of Lung Cancer;Jun2012, Vol. 11 Issue 1, p1 

    Immunotherapy was long considered as an attractive modality in the treatment of lung cancer. However, clinical successes were hampered by the inability to achieve potent activation of the antitumor immune system and effectively overcome the immune suppressive environment associated with lung...

  • Lung Cancer – Time to Move on from Chemotherapy. Carney, Desmond N. // New England Journal of Medicine;1/10/2002, Vol. 346 Issue 2, p126 

    The article focuses on the author's views on the treatment of lung cancer. He refers to recent studies that investigate the combination-chemotherapy regimens for treating small-cell lung cancer and advanced, inoperable non-small-cell lung cancer. The author cites the results of the studies,...

  • Emerging therapeutic agents for lung cancer. Dholaria, Bhagirathbhai; Hammond, William; Shreders, Amanda; Lou, Yanyan // Journal of Hematology & Oncology;12/9/2016, Vol. 9, p1 

    Lung cancer continues to be the most common cause of cancer-related mortality worldwide. Recent advances in molecular diagnostics and immunotherapeutics have propelled the rapid development of novel treatment agents across all cancer subtypes, including lung cancer. Additionally, more...

  • Re: Akt Phosphorylation and Gefitinib Efficacy in Patients With Advanced Non-Small-Cell Lung Cancer. De Braud, Filippo; De Pas, Tommaso; Spaggiari, Lorenzo; Veronesi, Guilia; Curigliano, Giuseppe; Noberasco, Cristina; Pelosi, Giuseppe // JNCI: Journal of the National Cancer Institute;3/16/2005, Vol. 97 Issue 6, p461 

    Presents a letter to the editor concerning Akt phosphor and gefitinib efficacy in patients with advanced non-small-cell lung cancer.

  • PD-1/PD-L1 pathway in non-small-cell lung cancer and its relation with EGFR mutation. Mei Ji; Yan Liu; Qing Li; Xiao-Dong Li; Wei-Qing Zhao; Hanze Zhang; Xiaofei Zhang; Jing-Ting Jiang; Chang-Ping Wu // Journal of Translational Medicine;2015, Vol. 13 Issue 1, p338 

    Immunotherapy has become a crucial modality for non-small-cell lung cancer treatment. Recently, two immune checkpoints, PD-1 and PD-L1, have emerged as important targets for immunotherapy. Their antitumor efficacy has been confirmed by in vitro and in vivo studies. But the correlation between...

  • Editorial Comment: Recent advances in our understanding of lung cancer visceral pleural invasion and other forms of minimal invasion: implications for the next TNM classification. Butnor, Kelly J.; Travis, William D. // European Journal of Cardio-Thoracic Surgery;Feb2013, Vol. 43 Issue 2, p309 

    The author reflects on the recent advancements in the prognosis for visceral pleural invasion in lung cancer. He states that the visceral pleura (VP) act as an adverse prognostic factor in non-small-cell lung carcinoma(NSCLC). The author suggests to conduct further studies for identifying the...

  • Crizotinib.  // Reactions Weekly;May2015, Vol. 1551 Issue 1, p94 

    An abstract of the article "Development of renal cysts after crizotinib treatment in advanced ALK-positive non-small-cell lung cancer,"

  • Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. Shafique, Michael R; Robinson, Lary A; Antonia, Scott // Cancer Management & Research;May2018, Vol. 10, p931 

    Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite improvements in the treatment of stage IV...

  • New developments in the treatment of advanced squamous cell lung cancer: focus on afatinib. Hirsh, Vera // OncoTargets & Therapy;May2017, Vol. 10, p2513 

    Until recently, few treatment options existed for the treatment of squamous cell carcinoma (SqCC) of the lung, especially in the second-line setting following platinum-based chemotherapy. Accordingly, outcomes in this subtype of non-small-cell lung cancer (NSCLC) were generally poor. In this...

  • Strengths and Weaknesses of Immunotherapy for Advanced Non-Small-Cell Lung Cancer: A Meta-Analysis of 12 Randomized Controlled Trials. Juan Wang; Ze-Hong Zou; Hong-Lin Xia; Jian-Xing He; Nan-Shan Zhong; Ai-Lin Tao // PLoS ONE;Mar2012, Vol. 7 Issue 3, p1 

    Background: Lung cancer is one of the leading causes of cancer death worldwide. Non-small-cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. Immunotherapy has yielded no consistent benefit to date for those patients. Assessing the objective efficacy and safety of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics